0000000000067913

AUTHOR

Tsioufis K

showing 3 related works from this author

Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic.

2020

SUMMARY: The coronavirus disease 2019 (COVID-19) pandemic considerably affects health, wellbeing, social, economic and other aspects of daily life. The impact of COVID-19 on blood pressure (BP) control and hypertension remains insufficiently explored. We therefore provide a comprehensive review of the potential changes in lifestyle factors and behaviours as well as environmental changes likely to influence BP control and cardiovascular risk during the pandemic. This includes the impact on physical activity, dietary patterns, alcohol consumption and the resulting consequences, for example increases in body weight. Other risk factors for increases in BP and cardiovascular risk such as smoking…

Psychologic stressCoronavirus disease 2019 (COVID-19)Physiology030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsEnvironmental healthPandemicInternal MedicineHumansMedicine030212 general & internal medicineRisk factorLife StylePandemicsSocioeconomic statuscardiovascular risk coronavirus disease 2019 diet environmental hypertension life style psychological salt severe acute respiratory syndrome coronavirus 2SARS-CoV-2business.industrySmokingCOVID-19Diurnal rhythmsLifestyle factorsBlood pressureSocioeconomic FactorsHypertensionbusinessCardiology and Cardiovascular MedicineStress Psychological
researchProduct

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology a…

2016

ABI : ankle–brachial (blood pressure) index ABPM : ambulatory blood pressure monitoring ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE-I : angiotensin-converting enzyme inhibitor ACS : acute coronary syndromes ADVANCE : Action in Diabetes and Vascular disease: PreterAx

Cost-Benefit AnalysisGeneral Practice030204 cardiovascular system & hematologyGuidelineDiabete0302 clinical medicineHyperlipidemiaStakeholderMedicine030212 general & internal medicineMultiple Chronic ConditionsPractice Patterns Physicians'Societies MedicalRisk assessmenteducation.field_of_studyCardiac RehabilitationDiabetesRehabilitationSmokingPsychosocial factorAge FactorsLipidMiddle AgedPrimary carePedigreeEuropeCardiovascular DiseasesPsychosocial factorsHypertensionBlood pressureDiet HealthyRisk assessmentCardiology and Cardiovascular MedicineAdultDiagnostic Imagingmedicine.medical_specialtyAmbulatory blood pressurePopulationPopulationCardiologyHealthy lifestyleHyperlipidemiasHealth PromotionDiabetic angiopathyGuidelinesRisk Assessment03 medical and health sciencesSex FactorsDiabetes mellitusJournal ArticleHumansClinical settingsHealthy LifestyleIntensive care medicineeducationExerciseAntihypertensive AgentsNutritionAgedbusiness.industryVascular diseasePhysical activityPreventionmedicine.diseasebody regionsClinical settingBlood pressureRisk managementSocioeconomic FactorsSmoking CessationJoint Esc GuidelinesbusinessBiomarkersDiabetic Angiopathies
researchProduct